Drug Shortages Part 2- the Scramble Continues

In my last post, I wrote about the nationwide shortage of Doxil, a drug used primarily to treat recurrent ovarian cancer.  In turns out that not only is there a Doxil shortage.  Three other mainline chemotherapies for ovarian cancer, carboplatin, cisplatin and taxol,  are in short supply.  I learned about the taxol shortage from a new friend on an ovarian cancer website.  Her clinic, not too far from where I live, has run out of taxol.  Luckily I get my infusions at a major medical center which still has a supply of these three drugs even though it does not have Doxil.

Doxil is available again for special cases, which unfortunately do not include me because I have not yet started treatment with Doxil.

Important Updates on DOXIL^® Shortage (8/5/2011)
We remain committed to restoring the availability of DOXIL^® (doxorubicin HCl liposome injection). A modest supply is now available through the DOXIL^® C.A.R.E.S. (Creating Awareness & Reinforcing Education Support) Physician Access Program.
To help ensure that patients currently on DOXIL^® receive the amount of DOXIL^® necessary to continue their course of therapy, we have set up the DOXIL^® C.A.R.E.S. Physician Access Program, a physician allocation process to obtain newly available DOXIL^® supply.
As DOXIL^® supply will remain intermittently available in the coming months, first priority will be given to patients currently on DOXIL^®. We continue to recommend that no new patients start therapy with DOXIL^® until adequate supply becomes available. (emphasis added)

So I could go for an indeterminate time not getting the drug that my oncologist says best increases my odds for a decent remission.  I am starting to feel the need to scramble myself.


According to the American Society of Health System Pharmacists, drug shortages currently affect about 200 medications in the United States, including antibiotics. The FDA reports record shortages for 2010 and projects more record shortages for 2011.  But the FDA has no power to require drug manufacturers to explain why there are shortages and effectively must beg the manufacturers to keep it informed.


The only real reason for these shortages is the economics for Big Pharma, which makes more money from new drugs, antidepressants and potency pills than generic chemotherapy drugs.  Dr. Ezekiel Emmanuel in the New York Times (August 7, 2011) explains:

Only the older but curative cancer drugs — drugs that can cost as little as $3 per dose — have become unavailable. Most of these drugs have no substitutes, but, crazy as it seems, in some cases these shortages are forcing doctors to use brand-name drugs at more than 100 times the cost. Only about 10 percent of the shortages can be attributed to a lack of raw materials and essential ingredients to manufacture the drugs. Most shortages appear instead to be the consequence of corporate decisions to cease production, or interruptions in production caused by money or quality problems, which manufacturers do not appear to be in a rush to fix.

Senators Schumer and Klobucher have introduced a bill, Preserving Access to Life-Saving Medications Act, which would require manufacturers to report shortages  and reasons for the shortages to the FDA. A similar bill has been introduced in the House.  See comparison of the two bills here.  Hearings are planned for the fall and hopefully manufacturers will become more accountable for their profit driven decisions about what drugs to produce.  I hope so.  My fellow cancer warriors and I cannot fight the good fight if the drugs aren't even available.